Leaf Biotech

About Leaf Biotech

Hefei Leaf Biotechnology Co., Ltd. is a high-tech enterprise focused on the research, development, and production of bio-based materials as sustainable alternatives to petroleum-based chemicals. Founded in July 2014 by its legal representative, Xu Hai, the company originated from Professor Fu Yao's research team at the University of Science and Technology of China, which began investigating the synthesis of the key bio-based monomer 2,5-Furandicarboxylic acid (FDCA) in 2010. Leaf Biotech is a specialist in the industrialization of furan-based materials, which offer a low-carbon footprint and superior performance for extensive applications.

The company's business model is centered on manufacturing and supplying these advanced materials, operating as a factory that also fulfills custom orders for industries requiring intermediates and pharmaceutical raw materials. Its primary products include FDCA, which is a green substitute for terephthalic acid (PTA), 5-Hydroxymethylfurfural (HMF), and the downstream polymer Polyethylene Furanoate (PEF), a fully bio-based and recyclable substitute for PET plastic. Its flagship product, BioFleax™ (PEF), is synthesized from FDCA and is positioned as a next-generation polymer for partners in the food and beverage, apparel, consumer electronics, and automotive industries. These materials are produced by upcycling agricultural and textile waste.

Leaf Biotech has achieved significant industrial milestones, launching the world's first kiloton-scale FDCA production line in 2022. The company is expanding its capacity with plans to complete a 25,000-ton FDCA production line by 2025. Supported by multiple funding rounds, including a Series B of nearly 200 million yuan, the company is scaling its production capabilities and process optimization. This positions Leaf Biotech at the forefront of the global industrialization of furan-based materials.